End of the Road? Philippine Jeepneys Face Uncertain Future 

In this photo taken on April 5, 2024, jeepneys commute along a street in Manila. (AFP)
In this photo taken on April 5, 2024, jeepneys commute along a street in Manila. (AFP)
TT

End of the Road? Philippine Jeepneys Face Uncertain Future 

In this photo taken on April 5, 2024, jeepneys commute along a street in Manila. (AFP)
In this photo taken on April 5, 2024, jeepneys commute along a street in Manila. (AFP)

The first jeepneys rolled onto the streets of the Philippines just after World War II -- noisy, smoke-belching vehicles initially made from leftover US Jeeps that became a national symbol.

Seven decades later, the colorfully decorated vehicles face an existential threat from a plan to replace them with modern mini-buses.

Easy to fix and cheap to ride, the vehicles grew in size and length to become the backbone of the country's transport system, carrying passengers, goods and even visiting popes.

But the government's plan to phase out jeepneys in an effort to modernize the country's chaotic public transport network has put the future of the iconic vehicles in doubt.

"It was a heavy blow," Leonard Sarao, operations supervisor of jeepney maker Sarao Motors, told AFP.

Sarao Motors was one of the first companies to produce jeepneys after founder Leonardo Sarao Sr gave up driving horse-drawn buggies to make motorized public transport in the early 1950s.

Production at the family-owned company's sprawling facility in the capital Manila peaked in the 1970s and 1980s, with workers making 50 to 60 jeepneys per month.

Demand began to fall over the following decades as other transport options became available. By 2014, Sarao Motors was producing as few as 10 jeepneys per month.

But it was the government's launch of the jeepney phase-out program in 2017 that slammed the brakes on production.

The now drastically downsized workforce produces one jeepney every four to six months, said Sarao, the grandson of Sarao Sr.

"We've had customers that have been around since the '50s, so they've been purchasing jeepneys, making their fleet bigger," said Sarao, 31.

"With this new program there have been a lot of doubts or fears that if they purchase a brand new jeepney will they still be able to use it a couple of years down the road?"

'We can't afford the price'

While Sarao Motors can produce modern jeepneys that meet the government's environmental and safety specifications, they are "three to four times the price of a traditional jeepney", Sarao said.

In the seven years since the phase-out program was launched there have been multiple delays in its implementation due to protests and Covid-19.

Operators now have until April 30 to join a cooperative and then gradually replace their fleet with modern vehicles that are safer, more comfortable and less polluting.

Cooperatives will be able to access bank financing and receive a government subsidy for each vehicle to ease the financial burden of the transition.

But drivers opposed to the plan argue that buying a new vehicle will bury them in debt and they will not be able to earn enough money to repay their loans and make a living.

"It's difficult for us to get a modern jeepney... we can't afford the price," said Julio Dimaunahan, 57, who operates a jeepney in Manila and has joined a cooperative.

"Even now our pockets are hurting because of the little profits we get as operators," he said pointing to increased competition from motorbike-hailing services.

Jeepney operator Flocerfida Majadas, 62, said she was worried about the future of her drivers if she were to go broke.

"Our concern is that we may not be able to pay our liabilities," Majadas said, referring to bank loans.

"If we're not able to pay, the bank will repossess the modern jeepneys. If the bank repossesses them what will happen to our staff?"

Cheap and easy to fix

While jeepneys now vie with buses, vans and motorbikes for passengers, they are still a common sight and sound in the archipelago nation.

Often brightly painted and with an exhaust that sounds like a trumpet, jeepneys cost passengers as little as 13 pesos (23 cents) to ride and their second-hand diesel truck engines are easy to fix.

"Once a customer buys a jeepney from us any mechanic in the provinces or the far-flung regions can fix it," Sarao said.

But the modern mini-buses the government would like to replace them with are more high-tech, with European emission standard engines or electric motors, WiFi, CCTV and air-conditioning.

"If it breaks down, where will we get the money to fix it?" asked Dimaunahan.

Sarao said his family's company could not compete with the capacity of overseas manufacturers to mass produce vehicles.

But he said jeepneys made by Sarao Motors were cheaper than the imported mini-buses and higher quality.

"The way we do things here is everything is hand-made so at least we do quality control of these units to make sure the panels don't fall off, the welds are completed," he said.

"When you speed things up that's where things can go wrong."

'Spirit of the jeepney'

Teodoro Caparino, who has been driving a jeepney for 35 years, hopes the government will decide to fix existing jeepneys rather than replace them with "Chinese-made vehicles".

"Our families will starve if we do not get to drive our jeepneys... all we know is driving," Caparino, 60, said.

While the jeepney in its current form might be nearing the end of the road, Sarao said he hoped the "essence" of the vehicle would survive.

"It may look bigger, it may look wider and longer, but as long as the essence of how it's supposed to look like or the spirit of the jeepney is still there, I still think it's going to be the jeepney."



Mexican Baby Monkey Finds Comfort in Plush Companion

A baby monkey named Yuji drinks milk while receiving care at a special care center at the zoo in Guadalajara, Mexico, Wednesday, April 15, 2026. (AP Photo/Refugio Ruiz)
A baby monkey named Yuji drinks milk while receiving care at a special care center at the zoo in Guadalajara, Mexico, Wednesday, April 15, 2026. (AP Photo/Refugio Ruiz)
TT

Mexican Baby Monkey Finds Comfort in Plush Companion

A baby monkey named Yuji drinks milk while receiving care at a special care center at the zoo in Guadalajara, Mexico, Wednesday, April 15, 2026. (AP Photo/Refugio Ruiz)
A baby monkey named Yuji drinks milk while receiving care at a special care center at the zoo in Guadalajara, Mexico, Wednesday, April 15, 2026. (AP Photo/Refugio Ruiz)

Yuji, a 6-week-old patas monkey in Mexico, wakes up every day clinging to a stuffed dog. More than a toy, this plush companion acts as a surrogate mom after the tiny primate was rejected by his own mother, Kamaria, a first-time parent unable to form a maternal bond.

Weighing a mere 673 grams (1.4 pounds), Yuji represents the most recent case of assisted rearing at the Guadalajara Zoo in western Mexico.

The story of Yuji has captured the attention of the Mexican public, drawing parallels to Punch, the Japanese macaque that went viral on social media after growing up clinging to a stuffed orangutan following his mother’s rejection, The Associated Press reported.

Unlike Punch, Yuji has not yet had physical contact with other members of his species; he spends most of his time inside a monkey crate at the Guadalajara Zoo’s Comprehensive Center for Animal Medicine and Welfare, CIMBA, where he is under the care of 12 veterinarians and biologists.

No date has been set for Yuji’s transfer to a habitat shared by 12 other adult patas monkeys and three other infants. That will depend on when he is weaned from a milk-only diet and starts an adult diet complete with fruits and vegetables, said veterinarian Iván Reynoso Ruiz, head of the primate section at the Guadalajara Zoo. That could happen when Yuji is around 6 months old, he said.

Just hours after giving birth on March 3, Kamaria began exhibiting irregular behavior. She struggled to hold her firstborn correctly, leaving the infant unable to secure a grip on its mother.

After noticing a problem, keepers separated the mother from her newborn, who weighed just 443 grams (less than a pound) and required immediate placement in an incubator at CIMBA to stabilize his temperature and safeguard his health, Reynoso Ruiz said.

This was the start of the infant's assisted rearing, a process often used by zoos to protect the health and development of at-risk offspring. A caregiver named him Yuji after a popular Japanese manga character.

During his first few weeks, Yuji was under round-the-clock supervision and was bottle-fed fortified milk.

From the start, Yuji was given a stuffed animal for comfort. Reynoso Ruiz explained that the toy fulfills the role of a mother by serving as his primary source of security. To maintain hygiene, staff rotate the original stuffed dog with two other toys — a bear and a monkey — to ensure he always has a clean companion.

To stimulate his development, caregivers outfitted Yuji’s crate with a small hammock and ropes. As he began gaining weight and sleeping for longer intervals, his team adjusted his feeding schedule. Yuji now receives the first of his four daily bottles at 7:00 a.m.

While the stories of Punch and Yuji have been popular on social media, some animal rights advocates oppose the practice of assisted rearing.

Diana Valencia, an animal rights activist, argues that there is no substitute for a natural habitat, and that animals “have the right to be born, grow, develop, and die where they belong.”

Responding to these criticisms, the Guadalajara Zoo’s primate expert emphasized that modern zoos provide a unique opportunity to protect species from global threats. He said the intervention was a matter of life or death, and that Yuji likely would have perished in the wild without a “second chance” at survival.


Trump's Triumphal Arch Gets Official Name

White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
TT

Trump's Triumphal Arch Gets Official Name

White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP

It's been dubbed the "Arc de Trump." But now President Donald Trump's latest building project has an official name -- the "United States Triumphal Arch."

White House Press Secretary Karoline Leavitt revealed the formal title on Wednesday, saying the giant structure was being built to mark the 250th anniversary of US independence, AFP reported.

"In honor of this historic occasion, President Trump and the Department of Interior will submit plans for the United States Triumphal Arch," Leavitt told reporters.

Showing off a picture that she initially held upside down, Leavitt said the "monumental" arch would stand 250 feet (76.2 meters) tall "in honor of 250 years."

Its colossal height, including a huge golden Lady Liberty statue on top, means it will dwarf perhaps its most famous predecessor, the Arc de Triomphe in Paris, which stands at 164 feet.

In fact it is set to be the largest structure of its kind in the world, pipping Mexico City's Monument to the Revolution and knocking Pyongyang's Arch of Triumph to third place.

Plans for the arch were first revealed in October when AFP journalists spotted a model on Trump's desk in the Oval Office, after which it was quickly dubbed the "Arc de Trump" by US media.

Trump revealed the first full renderings for the structure last Friday.

The arch is one of several architectural projects -- including the construction of a gigantic White House ballroom and renovations to the Kennedy Center for the Performing Arts -- that Trump has undertaken to leave a mark on Washington in his second term.

Critics say the gold-accented arch, which will tower over the 99-foot-tall Lincoln Memorial, is a monument to the 79-year-old Trump's vanity.

The arch will partly be funded by US taxpayers, getting $2 million in special funds from the US National Endowment for the Humanities, with up to $13 million in funds to match any donations, ABC News reported.

But Leavitt said it was aimed at celebrating US national pride.

"Long after everyone in this room is gone, our children and grandchildren will remain inspired by this national monument," she told reporters.


Much-hyped Alzheimer's Drugs Do Not Help Patients, Review Finds

New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
TT

Much-hyped Alzheimer's Drugs Do Not Help Patients, Review Finds

New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File

Drugs once hailed as a breakthrough in the fight against Alzheimer's disease do not meaningfully help patients, a major review found Thursday, however some experts criticized the research.

The review by the Cochrane organization -- which is considered the gold standard for analyzing existing evidence -- looked at drugs that target a plaque called amyloids which builds up in the brains of Alzheimer's patients.

Researchers have long sought a way to eliminate this plaque, believing it could be the cause of the most common form of dementia which affects millions of elderly people every year, said AFP.

After decades of costly yet unsuccessful research, two anti-amyloid drugs called lecanemab and donanemab were initially hailed as gamechangers that finally offered a way to slow the progress of the debilitating disease.

Both drugs were approved by the United States and European Union over the last few years.

However concerns about their effectiveness, cost and side effects including an increased risk of brain swelling and bleeding have since prompted caution. State-run health services in the UK and France have refused to cover the drugs.

The new Cochrane review combined data from 17 clinical trials that included a total of more than 20,000 people with mild cognitive impairment or early dementia.

The trials, which took place over roughly 18 months, studied seven different anti-amyloid drugs.

Only one of the trials examined donanemab -- sold under the name Kisunla by US pharma giant Eli Lilly -- while one studied lecanemab, sold as Leqembi by Biogen and Eisai.

While early trials suggested these drugs made a statistically significant difference, this did not translate into "something clinically meaningful for patients," lead study author Francesco Nonino of Italy's IRCCS institute told a press conference.

Brain scans showed that the drugs successfully removed amyloids, the researchers emphasized.

This means "the idea that removing amyloids will benefit patients was refuted by our results," said study co-author Edo Richard of Radboud University Medical Center in the Netherlands.

- 'Not delivering on promise' -

Richard, who has previously expressed skepticism about anti-amyloid drugs, said he hopes efforts targeting other mechanisms that potentially cause Alzheimer's lead to more effective drugs in the future.

British biologist John Hardy, who first developed the amyloid hypothesis in the 1990s, criticized the review for lumping together data about lecanemab and donanemab along with drugs that are known to be ineffective, therefore dragging down the overall average.

"This is a silly paper which should not have been published," Hardy told AFP, disclosing that he has consulted for Eli Lilly, Biogen and Eisai.

In response to such questions, Richard said that while the drugs included in the study may work in different ways, they all have the same target: amyloid beta proteins.

Australian neuroscientist Bryce Vissel, who was not involved in the research, said it "does not prove amyloid has no role in Alzheimer's, and it does not rule out future amyloid-directed therapies that may yet help patients".

"But it does show that the current generation of anti-amyloid drugs is not delivering the promise that has surrounded it."